Pacagen
Pacagen is a private biotech consumer health company that sells allergen-neutralizing sprays and supplements for cat, dog, and dust mite allergies, using proprietary alpaca-derived nanobody technology (WhiskerBlock™, EnviroBlock™) to neutralize allergens at the molecular level before they trigger reactions, sold direct-to-consumer to allergy sufferers and pet owners.
- Company typePrivate
- Founded2023
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Pacagen does
Pacagen is a private biotechnology consumer health company founded in 2023 that develops and sells allergen-neutralizing products for households with cat, dog, and dust mite allergies. The company's proprietary technology platform, WhiskerBlock™ and EnviroBlock™, consists of alpaca-derived single-domain antibodies (nanobodies) engineered by screening over one billion antibody variants for binding affinity and specificity against the major indoor allergens Fel d 1, Can f 1, Can f 2, Der p 1, and Der p 2. Laboratory studies report up to 98% neutralization of cat allergen tetramers within minutes at concentrations as low as 150 ng/mL, and up to 93% blocking of dust mite allergen secondary activities. The product portfolio comprises three environmental sprays (cat, dog, dust), a cat food topper supplement that neutralizes Fel d 1 at the source in the cat's saliva, refill packs, and digital gift cards — all priced starting at $46.40 per unit.
Pacagen operates a direct-to-consumer go-to-market through its Shopify-powered storefront at pacagen.com, supplemented by a wholesale portal, an ambassador/affiliate program, healthcare professional endorsements (dermatologists, veterinarians), SEO/content marketing, and a TV campaign that launched in December 2024. The company reports serving over 70,000 allergen-free households and selling more than 100,000 units, with 97% of customers reporting fewer allergic flare-ups and a 4-week home-use study of 97 households showing 90.7% reported significant improvement. Product-led growth is the primary GTM motion, with referral and subscription/repeat-purchase mechanics built around consumable sprays and supplements. The company is privately held, headquartered in New York, NY, founded by Princeton researchers Dr. Evan Zhao (CEO) and Dr. Siyang Han, and brought in Digitalis Ventures and Maveron as institutional investors in a January 2025 funding round on top of approximately $2 million in founder-funded R&D.
Pacagen firmographics
Firmographics- Name
- Pacagen
- Legal name
- Pacagen, Inc.
- Website
- https://pacagen.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pacagen is a private biotech consumer health company that sells allergen-neutralizing sprays and supplements for cat, dog, and dust mite allergies, using proprietary alpaca-derived nanobody technology (WhiskerBlock™, EnviroBlock™) to neutralize allergens at the molecular level before they trigger reactions, sold direct-to-consumer to allergy sufferers and pet owners.
- Ownership category
- akta.pro rank
Pacagen industry classification
Industry- Product category
- Consumer Health Products
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Dog and Cat Food Manufacturing (311111), Animal Food Manufacturing (3111)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)
- akta.pro secondary industries
- Allergy & Anti-Inflammatory Supplements (HLAMALAL), Gastrointestinal & Food Sensitivity/Hypoallergenic Diets (HLAMAHAM), Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
Keywords
Where Pacagen is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Pacagen business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Infrastructure
Revenue model
- Direct-to-Consumer Product Sales: Pacagen generates revenue through direct online sales of allergen-neutralizing sprays and supplements via pacagen.com. Products include Cat Allergen Neutralizing Spray ($46.40), Dog Allergen Neutralizing Spray ($46.40), Dust Allergen Neutralizing Spray ($46.40), Cat Allergen Reducing Supplement ($46.40), refill packs ($58), and digital gift cards ($25-$300). The company sells directly to consumers through its e-commerce platform with a 60-90 day money-back guarantee.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Allergen Neutralizing Sprays (Cat, Dog, Dust) |
| Unit Pricing | Pay-as-you-go | Cat Allergen Reducing Supplement |
| Unit Pricing | One-time purchase | Digital Gift Cards |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
Pacagen product offering
Product offeringCore offering
Pacagen develops and sells allergen-neutralizing consumer sprays and supplements that target cat, dog, and dust mite allergens using proprietary alpaca-derived single-domain antibody (nanobody) protein technology called WhiskerBlock™ and EnviroBlock™. The products bind to allergenic proteins (Fel d 1, Can f 1, Can f 2, Der p 1, Der p 2) at the molecular level to prevent allergic reactions before they occur, and are sold direct-to-consumer through pacagen.com and via wholesale and ambassador channels.
Product overview
Pacagen is a biotechnology company that offers a portfolio of allergen-neutralizing consumer products for cat, dog, and dust mite allergies. The core portfolio consists of three Allergen Neutralizing Sprays (Cat, Dog, and Dust) using WhiskerBlock and EnviroBlock protein technologies, a Cat Allergen Reducing Supplement (food topper) using the same WhiskerBlock Alpha technology, and refill packs for the sprays. The products work by binding to and neutralizing allergenic proteins at the molecular level in the home environment, rather than treating symptoms after allergic reactions occur. All products are offered individually, in bundles, or via gift cards.
Differentiator
Problem solved
Functional benefit
Products and services
- Cat Allergen Neutralizing Spray
Quantifiable outcome
- 97% of Pacagen users reported fewer allergic flare ups
- +3 more outcomes
Companies that use Pacagen
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles2 records
Pacagen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Pacagen partnerships and signals
Strategic signalScale indicators7 records
Recent moves6 records
Expansion highlights6 records
Pacagen competitors and assessment
Company assessmentBroad incumbents
- ALK-Abelló: Global leader in allergy immunotherapy (SCIT/SLIT) for cat, dog, dust mite, and pollen allergens. Overlaps with Pacagen on the same allergens (Fel d 1, Der p 1/2) but addresses them via sublingual immunotherapy rather than environmental protein neutralization.
- Stallergenes Greer: Major allergy diagnosis and immunotherapy company covering the same major allergen families (cats, dogs, dust mites). Competes indirectly with Pacagen for the same allergy-sufferer wallet, though via prescription immunotherapy rather than consumer products.
- Blueair: Established air purifier brand (now part of Unilever) with explicit allergy-relief positioning. Offers an alternative, capital-good approach to indoor allergen reduction that competes with Pacagen's spray-based neutralization.
- Bayer Consumer Health (Claritin / Allegra): Owner of leading OTC antihistamine brands Claritin and Allegra, which dominate the consumer allergy category at much lower price points. Represents Pacagen's primary indirect substitute — a fundamentally different mechanism but the same end-customer.
- Sanofi Consumer Healthcare (Zyrtec / Xyzal): Owns Zyrtec and Xyzal, two of the top-selling OTC antihistamines in the US. Competes with Pacagen for the same allergy-sufferer wallet via a low-cost daily pill rather than an environmental protein spray.
Direct peers
- Pet Honesty: Direct-to-consumer pet supplement brand (allergy support, skin & coat, calming chews) sold primarily through Amazon and DTC. Competes with Pacagen for the same 'allergy-prone pet household' segment via consumable supplements.
- Nestlé Purina: Commercialized Pro Plan LiveClear, a cat food formulated to reduce Fel d 1 on cat hair — directly competing with Pacagen's Cat Allergen Reducing Supplement in the same consumer use case (reducing active cat allergens via ingested product) at much greater scale.
- Zesty Paws: DTC pet health supplement brand offering a broad portfolio of cat and dog functional supplements (skin & coat, immune, calming). Pacagen's Cat Allergen Reducing Supplement competes for the same shelf-of-mind in the premium pet supplement category.
Emerging players
- Molekule: Premium DTC air purifier brand explicitly marketed on allergen and pollutant reduction for allergy and asthma sufferers. Competes with Pacagen for the same consumer mindshare around indoor allergen management, albeit via hardware rather than consumables.
- AllerMates: Consumer brand offering allergy-related products for pet households and allergy sufferers (including pet allergen reduction products). A smaller-scale, thematically-overlapping peer in the consumer allergen-management space.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Pacagen social profiles
Digital presencePacagen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pacagen leadership team
Management profileNumber of profiles
Profiles6 records
Pacagen funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pacagen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pacagen
What does Pacagen do?
Pacagen develops and sells allergen-neutralizing consumer sprays and supplements that target cat, dog, and dust mite allergens using proprietary alpaca-derived single-domain antibody (nanobody) protein technology called WhiskerBlock™ and EnviroBlock™. The products bind to allergenic proteins (Fel d 1, Can f 1, Can f 2, Der p 1, Der p 2) at the molecular level to prevent allergic reactions before they occur, and are sold direct-to-consumer through pacagen.com and via wholesale and ambassador channels.
Is Pacagen a public or private company?
Pacagen is a private company. It is classified as venture growth investor backed and is currently operating.
When was Pacagen founded?
Pacagen was founded in 2023. It employs 11 to 50 people.
Where is Pacagen based?
Pacagen is headquartered in Cambridge, United States, in the North America region.
How does Pacagen make money?
One revenue line is on record: direct-to-Consumer Product Sales.
Who are Pacagen's main competitors?
Broad incumbents on record are ALK-Abelló, Stallergenes Greer, Blueair, Bayer Consumer Health (Claritin / Allegra) and Sanofi Consumer Healthcare (Zyrtec / Xyzal). Direct peers are Pet Honesty, Nestlé Purina and Zesty Paws. Emerging players are Molekule and AllerMates.
Does Pacagen have an API?
No public API is recorded for Pacagen.
What industry is Pacagen in?
Pacagen's product category is Consumer Health Products. Its primary akta.pro industry code is HLAAAEAI, Allergy Immunotherapy Biologics (allergen extracts, desensitization), with a secondary code of HLAMALAL, Allergy & Anti-Inflammatory Supplements. Its NAICS code is 325414 and its SIC code is 2836.